Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Daneb Gonzalez

Nurse Practitioner, Pediatrics Miami, FL Nurse Practitioner

NPI 1548572506 CMS profile 11168772

1695 Nw 110Th Ave Ste 317, Miami, FL 33172

Open in the dashboard

General payments

$8,128

308 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daneb Gonzalez of Miami, FL is reported in the CMS Open Payments database as having received $8,128 across 308 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,462 59
2024 General $2,464 69
2023 General $1,649 72
2022 General $1,224 49
2021 General $1,329 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daneb Gonzalez
  • Nurse Practitioner, Pediatrics median
  • Middle half of Nurse Practitioner, Pediatrics
  • National median

In program year 2025, general payments to Daneb Gonzalez were reported at $1,462. Among 7,458 Nurse Practitioner, Pediatrics profiles paid that year, the median was $93 and the middle half received between $35 and $201.

Show as a table
Year Daneb Gonzalez Nurse Practitioner, Pediatrics median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,329 $60 $23–$142 $132
2022 $1,224 $72 $27–$161 $149
2023 $1,649 $89 $35–$185 $160
2024 $2,464 $93 $34–$199 $164
2025 $1,462 $93 $35–$201 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. UCB, Inc. $2,337 57 payments
  2. Supernus Pharmaceuticals, Inc. $2,070 80 payments
  3. Corium, Inc. $903 39 payments
  4. Ironshore Pharmaceuticals Inc. $350 25 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $344 16 payments
  6. Neurelis, Inc. $309 14 payments
  7. Jazz Pharmaceuticals Inc. $263 8 payments
  8. Tris Pharma Inc $229 14 payments
  9. Biohaven Pharmaceuticals, Inc. $205 6 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $179 10 payments
  11. Other $938 39 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,128 308 payments
Products named General payments · program years 2021–2025
  1. Briviact $2,211 55 payments
  2. Qelbree Viloxazine Hydrochloride $1,699 57 payments
  3. Azstarys $903 39 payments
  4. NURTEC ODT $549 22 payments
  5. QELBREE Psychology $358 22 payments
  6. VALTOCO $309 14 payments
  7. JORNAY PM $308 23 payments
  8. Epidiolex $263 8 payments
  9. Dyanavel XR $206 13 payments
  10. VYVANSE $179 10 payments
  11. Other $1,098 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

308 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record